Latest News - Pfizer
Top Corporates Hub
Pfizer
Is Pfizer (PFE) Cheap As Its Enodia Deal Fuels Oncology Growth Hopes?
24.10.2026 00:14
Pfizer (PFE) is back in focus after signing a research collaboration and license agreement with Enodia Therapeutics that gives the drugmaker access to Enodia’s Sec61 inhibitor programs for potential oncology and specialty treatments. Pfizer’s agreement with Enodia lands at a time when momentum in the shares has been rebuilding, with a 30 day share price return of 6.56% and a 90 day gain of 22.37%. The 1 year total shareholder return of 29.79% contrasts with a weaker 5 year total shareholder...
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields
23.10.2026 08:30
Analysts highlight high-yield healthcare stocks Perrigo (7.09%), Pfizer (5.65%) and CVS Health (2.82%), with updated ratings and news.
How Much Downside Is Left In Moderna Stock?
23.10.2026 08:00
For questions about this article or underlying research, email help@trefis.com.
Pfizer (PFE) Signs New Drug Discovery Pact Focused On Sec61 Inhibitors
22.10.2026 04:30
Pfizer (NYSE:PFE) signed a new research collaboration and license agreement with Enodia Therapeutics to develop Sec61 inhibitors. The arrangement centers on small-molecule Sec61 blockers that Enodia is advancing using its proprietary discovery platform. Under the alliance, Pfizer gains rights to discover, develop and potentially commercialize drug candidates that emerge from Enodia's Sec61 programs. This Sec61-focused collaboration with Enodia is an important piece to weigh against the rest...
Moderna's Respiratory Portfolio Expands: Can It Reduce COVID Reliance?
21.10.2026 12:25
MRNA expands beyond COVID-19 with new RSV, flu and combination vaccines, but fierce competition could challenge its efforts to diversify revenue.
What Have Pfizer Stock Holders Really Earned?
21.10.2026 02:26
The dividend is probably the reason investors hold Pfizer (PFE), the maker of medicines such as Eliquis and Padcev. The stock yielded 5.8% at the October 19, 2026 close. Over the past five years, though, the share price has fallen far behind the S&P 500. So take a guess: once every dividend is counted, how did five years of owning Pfizer turn out next to the market.
What Happens To Merck Stock If Keytruda Sales Stop Growing?
21.10.2026 02:20
Shares of Merck (MRK) returned 76.2% over the past year, compared with 17.4% for the S&P 500. U.S. growth for the company's cancer drug Keytruda is set to slow. Management said on the August 4 call that U.S. Keytruda growth will moderate as the drug reaches peak penetration across several key indications. Barron's also reported on October 7 that a Dutch court barred Merck from selling subcutaneous Keytruda in eight European markets. So how much of what Merck sells is Keytruda.
Slate Medicines Strengthens Board of Directors with Appointment of Stephen K. Brannan, MD, and John D. Young
20.10.2026 11:00
RALEIGH, N.C., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Slate Medicines, Inc. (“Slate”), a clinical-stage biotechnology company committed to advancing innovative new therapies that may broaden the treatment paradigm and potentially improve outcomes for people with migraine and other headache disorders, today announced the appointment of Stephen K. Brannan, MD, and John D. Young to the company’s Board of Directors. Dr. Brannan brings more than 25 years of clinical development experience in CNS disorders
Maxion Therapeutics Appoints Biopharma Leader Mikael Dolsten to Board of Directors
20.10.2026 09:00
Former Pfizer Chief Scientific Officer and President of Worldwide Research, Development and Medical brings deep experience translating scientific innovation into life-changing medicines for patients CAMBRIDGE, United Kingdom, October 20, 2026 – Maxion Therapeutics, a biotechnology company developing antibody-based KnotBody® drugs for ion channel- and G protein-coupled receptor (GPCR)-driven diseases, today announced the appointment of Mikael Dolsten, MD, PhD, as an independent Non-Executive Dire
What Pfizer Bulls Got Right
20.10.2026 02:12
Pfizer spent 2026 stacking cancer headlines, from fresh breast cancer approvals to a multibillion dollar oncology alliance, even as quarterly profit swung from a US$2,885 million gain to a loss and net margin moved from 19.7% to 1.7% in the red. Investors who held Pfizer from the start of the year saw a 23.0% return, including dividends. If you were weighing a buy on 1 January, what needed to look credible about this reinvention story to take that risk? A Narrative on Simply Wall St is one...
Here's What $10,000 in Each of These 5 High-Yield Dividend Stocks Could Pay You in a Year
18.10.2026 14:50
These five high-yield dividend stocks are paying yields of 5.88% to 16.72% -- but beware of a few key risks.
JD Vance Touts TrumpRx Drug Price Push, Trump Accounts as ‘Economic Nationalism’ Wins Ahead Of Midterms
17.10.2026 02:22
JD Vance touted TrumpRx and Trump Accounts as key economic wins, highlighting prescription drug savings ahead of the midterm elections.
Tukysa Approval Might Change The Case For Investing In Pfizer Stock (PFE)
16.10.2026 04:30
Pfizer recently secured expanded FDA approval for TUKYSA as a chemotherapy free maintenance option in HER2 positive metastatic breast cancer and reported a wide slate of infectious disease vaccine data, including late stage Lyme, pneumococcal and RSV studies. The breadth of vaccine and oncology updates points to Pfizer leaning heavily on late stage pipelines and real world evidence to support future portfolio mix as older products face patent expiry and COVID sales pressure. We will now look...
Moderna Rallies 6% as Money Rotates Into Healthcare; BioNTech and Pfizer Edge Higher
15.10.2026 16:55
Money is leaving the AI trade and landing in healthcare, but one mRNA name is surging at a pace that leaves its closest peers far behind, and a clinical story from weeks ago may explain why.
This Company’s Products Kill People, But It Has A 6.2% Yield
15.10.2026 14:02
Altria's cigarettes kill hundreds of thousands of Americans every year, yet its stock is quietly outperforming the S&P 500 by a wide margin in 2024. The question investors now face says as much about ethics as it does about returns.
Why Did GME, BMBL, PFE Stocks Hit 52-Week Highs Today?
15.10.2026 03:47
Insider purchases, a multibillion-dollar acquisition and progress in vaccine research helped drive interest.
J&J Beat and Raised. The Stock Fell Anyway. Here’s What the Target Says
14.10.2026 11:15
Johnson and Johnson crushed earnings, raised guidance, and still watched its stock crater nearly 6% in a single session. Understanding what spooked investors reveals whether Tuesday's selloff is a trap or a warning.
Pfizer Showcases Clinical Advancements Across Infectious Diseases at IDWeek 2026
14.10.2026 10:45
NEW YORK, October 14, 2026--Pfizer Inc. (NYSE: PFE) will present data from more than 50 company-sponsored, investigator-sponsored and collaborative research abstracts across its infectious disease pipeline and portfolio at the upcoming IDWeek 2026 congress, held in Washington, D.C., from October 21-24, 2026. Data across 12 oral presentations will showcase the Company’s advancements in the prevention and treatment of infectious diseases.
Pfizer partners with Enodia Therapeutics in $500m drug deal
14.10.2026 08:40
Enodia Therapeutics will handle initial discovery work to identify, refine, and advance small-molecule candidates directed at multiple targets.
What Is Pfizer (PFE) Really Gaining From Its Sec61 Drug Discovery Deal?
13.10.2026 19:15
Pfizer (NYSE:PFE) agreed a research collaboration and licensing deal with Enodia Therapeutics to pursue Sec61-targeting small molecule drugs. Enodia grants Pfizer access to its proprietary Sec61 inhibitor platform, while Pfizer takes charge of clinical, regulatory, and commercial development. The partnership is structured to apply Sec61-directed molecules across multiple disease areas, adding a new discovery track to Pfizer's pipeline. This new Sec61-focused collaboration with Enodia...